Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis

2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis

(2018) Daniel Wendling et al.   JOINT BONE SPINE

Spondyloarthritis: An expanding cast of cellular actors

(2018) Daniel Wendling et al.   JOINT BONE SPINE

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab

(2018) María José Fobelo Lozano et al.   Journal of Crohns & Colitis

Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies

(2018) I-Tsu Chyuan et al.   MEDIATORS OF INFLAMMATION

IL-17 in the immunopathogenesis of spondyloarthritis

(2018) Leonie S. Taams et al.   Nature Reviews Rheumatology

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

(2018) Paul Emery et al.   PHARMACOECONOMICS

IL-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses

(2018) Leonieke J. J. van Mens et al.   Arthritis & Rheumatology

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

(2018) Stefan Siebert et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies

(2017) James C.-C. Wei et al.   International Journal of Rheumatic Diseases

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

(2017) Denis Poddubnyy et al.   RHEUMATOLOGY

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

(2017) Iain B McInnes et al.   RHEUMATOLOGY

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

(2017) H. Marzo-Ortega et al.   ARTHRITIS CARE & RESEARCH

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

(2016) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0113 No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

(2016) S. Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab (AIN457) in the treatment of ankylosing spondylitis

(2016) Jürgen Braun et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The gut in spondyloarthritis

(2016) Daniel Wendling   JOINT BONE SPINE

Ankylosing Spondylitis and Axial Spondyloarthritis

(2016) Joel D. Taurog et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)

(2016) Atul A. Deodhar et al.   Arthritis & Rheumatology

Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study

(2015) Xenofon Baraliakos et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study

(2015) Anna Moltó et al.   ANNALS OF THE RHEUMATIC DISEASES

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis

(2015) Francesco Ciccia et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab for treating plaque psoriasis

(2015) Brooke Rothstein et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

An overview of investigational new drugs for treating ankylosing spondylitis

(2015) Daniel Wendling   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Interleukin-17 targeted therapies in axial spondyloarthritis

(2015) Daniel Wendling   Immunotherapy

Spondyloarthritis: A concept or a disease?

(2015) Daniel Wendling et al.   JOINT BONE SPINE

The IL-23/Th 17 pathway in spondyloarthritis: The Royal Road?

(2015) Daniel Wendling et al.   JOINT BONE SPINE

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy

(2015) Erik Letko et al.   OPHTHALMOLOGY

IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities

(2014) D. T. S. L. Jansen et al.   RHEUMATOLOGY

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

(2013) Andrew D. Dick et al.   OPHTHALMOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: What's in a name?

(2012) Pascal Claudepierre et al.   JOINT BONE SPINE

Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis

(2012) Wei-Sheng Chen et al.   Journal of the Chinese Medical Association

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats

(2011) Simon Glatigny et al.   ARTHRITIS AND RHEUMATISM

Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response

(2011) Heiner Appel et al.   ARTHRITIS RESEARCH & THERAPY

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

(2009) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES